#NASDAQ #Liechtenstein #Vaduz #Implantica #RefluxStop

Implantica Joins Nasdaq's First North 25 Index

In a prestigious move for the medtech industry, Implantica AG has been announced as a new member of Nasdaq's First North 25 index, effective January 2, 2025. This decision comes during Nasdaq's latest semi-annual review, where it recognized Implantica as one of the leading and most traded shares within the Nasdaq Nordic First North Growth Market.

Based in Vaduz, Liechtenstein, Implantica is at the forefront of health technology innovations, particularly with its flagship product, RefluxStop™. This device aims to address a pervasive issue impacting roughly 1 billion people worldwide: acid reflux. Peter Forsell, CEO of Implantica, expressed his enthusiasm regarding the listing, emphasizing that it validates the growing interest from the investment community and highlights the company's ongoing commitment to advancing healthcare solutions.

The company has made significant strides in seeking regulatory approval, having already submitted two of three modules of the Pre-Market Approval (PMA) application to the FDA, which is crucial for its product's U.S. market introduction. Forsell noted that the interest among surgical professionals in the United States has surged following successful usability trials, presenting compelling clinical outcomes at various U.S. medical congresses.

A Transformational Device in Anti-Reflux Treatment

Implantica's RefluxStop™ is not only a treatment option but a potential game changer in the field of anti-reflux surgery. Unlike traditional surgical methods, which often lead to discomfort and complications by compressing the esophagus, RefluxStop™ functions by restoring the lower esophageal sphincter to its natural position without applying undue pressure. This innovative approach focuses on reconstructing all three components of the anti-reflux barrier, effectively allowing the body to address acid reflux naturally.

The results gathered from a 5-year study, which were accepted by the FDA for PMA submission, have been outstanding. Forsell is optimistic about receiving critical feedback from the FDA on the clinical module of their application in the near future. This optimism is further supported by the successful implementation of their technology in various surgical centers, which have yielded excellent results and high surgeon interest.

Industry Impact and Future Prospects

Implantica's entry into the First North 25 index aligns with broader trends within the medtech sector where innovative approaches and patient-centric devices are increasingly prioritized. The interest from investors symbolizes a pivotal moment not only for the company but also for the future of medical technologies that prioritize patient well-being and efficacy.

As Implantica prepares for its upcoming chapters, the company remains committed to advancing its eHealth capabilities. Their ongoing development pipeline includes advanced, patent-protected technologies designed to monitor health parameters and control treatments from within the body – demonstrating a forward-thinking approach to patient care. This dual focus on eHealth and innovative implant technologies can set the stage for Implantica to become a leader in modern healthcare solutions.

In conclusion, as Implantica AG steps into a new era with its inclusion in Nasdaq's First North 25 index, it stands poised to make significant contributions to the medical technology field, benefiting millions affected by gastroesophageal reflux disease and other conditions requiring advanced medical interventions. The future looks promising as they continue to push the boundaries of medical innovation.